Introduction {#Sec1}
============

Seasonal influenza is an acute respiratory infectious disease that can cause serious health problems. Seasonal influenza epidemics caused by influenza A and B viruses result in 3--5 million severe cases and 290,000--650,000 deaths worldwide; 5%--10% of adults and 20%--30% of children suffer from flu annually (World Health Organization, WHO [@CR37]). Seasonal influenza viruses undergo antigenic drift, which makes the conventional seasonal vaccines ineffective when the vaccine strains mismatch with the epidemic strains. Therefore, seasonal influenza vaccines must be updated regularly for effective prevention of influenza. The production time for conventional influenza vaccines can be lengthy. It takes 1--2 months to obtain vaccine strains using conventional reassortment technology or reverse genetics technology, followed by several more months for large-scale expansion of influenza vaccine using an ample supply of specific pathogen-free (SPF) chicken embryos. Generally, influenza vaccine production takes 3--6 months from the prediction of the epidemic strain to the ultimate production of the vaccine (Emanuel and Wertheimer [@CR9]). For more effective prevention of influenza, new vaccines are warranted to induce cross-protection and long-lasting immune responses (Erbelding*et al.*[@CR10]). Recently, great strides in influenza vaccine research have been made using conserved antigens of influenza virus. The highly conserved internal protein nucleoprotein (NP) and extracellular domain of matrix protein 2 (M2e) can induce cross-protection against influenza A virus, showing promise as candidate antigens for the development of a broad-spectrum influenza vaccine (Erbelding*et al.*[@CR10]; Zhang*et al.*[@CR42]; Kui*et al.*[@CR38]). Previously, we expressed a fusion protein of NP and M2e (NM2e) in *Escherichia coli* and showed that immunization with NM2e formulated with aluminum hydroxide gel protected mice from a lethal challenge with heterologous influenza virus (Wang *et al.*[@CR33]). Therefore, vaccination with recombinant NM2e fusion protein is a promising strategy for the development of a universal influenza vaccine. However, a new expression system is required to further optimize the NP- and M2e-based vaccine.

The vaccinia virus (Tiantan strain) was developed in China as a vaccination agent against smallpox, as documented by WHO (Fenner*et al.*[@CR100]). This strain was used to inoculate several individuals for \~50 years, playing a key role in the eradication of smallpox in China (Ruan [@CR29]). The Tiantan strain has favorable gene vector and vaccine characteristics, including a powerful multiplication capacity, wide host range, high capacity for insertion of a foreign gene, noncarcinogenicity, and induction of long-lasting immunity. Using the *TK* gene system of the Tiantan strain, this vaccinia virus has been developed successfully as a viral vector for various vaccine applications (Ruan [@CR29]) including hepatitis B virus (Chuai*et al.*[@CR4]), hepatitis C virus (Wen*et al.*[@CR36]), and severe acute respiratory syndrome coronavirus vaccines (Yan*et al.*[@CR39]). We have developed recombinant vaccinia viruses based on NP, M1, M2, and PB1 of influenza A virus (Huang*et al.*[@CR14]; Wang*et al.*[@CR32], [@CR35]). Several of our NP-based recombinant vaccinia viruses have induced a protective immune response in BALB/c mice. To develop a vaccine with broader protection, we constructed recombinant vaccinia viruses expressing various combinations of NP and M2e to exhibit their maximal antigenicity. BALB/c mice were immunized with the recombinant viruses to measure NP- and M2e-specific humoral and cellular immune responses as well as protective effect against lethal challenge with a heterologous influenza virus.

Materials and Methods {#Sec2}
=====================

Materials {#Sec3}
---------

β-Gal (40-1a) monoclonal antibody (sc-65670) and NP monoclonal antibody (5D8) (sc-80481) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). M2 monoclonal antibody (14C2) (ab5416) and Alexa Fluor^®^ 488-conjugated goat anti-mouse polyclonal antibodies were from Abcam (Cambridge, MA, USA). BD Cytometric Bead Array (CBA) Mouse Th1/Th2/Th17 Cytokine kit was purchased from BD (Franklin Lakes, NJ, USA). Peptides NP55--69 (RLIQNSLTIERMVLS; H-2d-restricted Th epitope), NP147--155 (TYQRTRALV; H-2d-restricted CTL epitope), and M2e pooled peptides (peptides of residues 1--15, 5--19, and 9--23) were synthesized by Beijing SciLight Biotechnology Ltd. Co. (Beijing, China).

Viruses {#Sec4}
-------

Vaccinia virus (Tiantan strain) and influenza A virus A/Puerto Rico/8/34 (PR8) (H1N1) (Wang*et al*. [@CR35]) were used in this study. Vaccinia virus (Tiantan strain) was amplified and titrated in primary chicken embryo fibroblasts (CEFs). The PR8 influenza virus was propagated in 9-day-old chicken embryos at 34 °C for 48 h, and the allantoic fluid was then collected and stored at − 70 °C until use. Mouse 50% lethal dose (MLD~50~) titer of the influenza virus PR8 was assessed in BALB/c mice before conducting the challenge experiments.

Construction of Plasmids and Recombinant Vaccinia Virus {#Sec5}
-------------------------------------------------------

Plasmid pJSC1175 contains two DNA fragments (*TKL* and *TKR*) derived from vaccinia virus Tiantan strain to facilitate homologous recombination with vaccinia virus in host cells. Between the two homology arms, there are p11 late promoter of vaccinia virus to regulate the *lacZ* gene and p7.5 early/late promoter of vaccinia virus to regulate the target genes. The pJSC1175 was linearized at a *Bam*H I restriction enzyme site immediately downstream the p7.5 promoter and further treated with calf intestinal alkaline phosphatase.

Plasmid pET30a-NM2e contains the fusion gene of full-length *NP* (498 amino acids) and the succeeding *M2e* (23 amino acids) from influenza A virus, A/Beijing/30/95 (H3N2) (BJ95) (Wang*et al.*[@CR33]). The *NP* and *M2e* fusion gene (referred to as *NPM2e*) was amplified from plasmid pET30a-NM2e by polymerase chain reaction (PCR) to introduce *Bam*H I site at each end. The *NPM2e* was digested by *Bam*H I, and inserted into the linearized plasmid pJSC1175. The resulting plasmid carrying *NPM2e* at the same orientation as the p7.5 promoter was designated as pJSC1175-NPM2e.

From plasmid pJSC1175-NPM2e, *M2e* and *NP* genes were amplified respectively, and fused (*M2e* preceding *NP*) by PCR to generate a fusion gene, *M2eNP*. DNA fragment containing four copies of M2e (from BJ95) was amplified from plasmid, pET9a-H4M2e, and fused to the 5′ terminus of full-length *NP* gene by PCR, resulting in fusion gene, *4M2eNP*. The DNA fragment containing four copies of *M2e* was also fused to the 5′ terminus of a *NP* gene (from BJ95) truncated at both ends (referred to as *NPs*, encodes 314 amino acids) that was amplified from plasmid pET9a-NPsM2e by PCR. The resulting fusion gene was named *4M2eNPs*. As the fusion genes *M2eNP*, *4M2eNP*, and *4M2eNPs* were engineered with *Bam*H I site at each end through PCR, they were cloned into linearized pJSC1175 as described above. The resulting plasmids were pJSC1175-M2eNP, pJSC1175-4M2eNP, and pJSC1175-4M2eNPs, respectively.

Recombinant vaccinia viruses were generated via homologous recombination, as described by Wang*et al.*([@CR35]). Briefly, CEFs were infected with vaccinia virus Tiantan strain at a multiplicity of infection of 0.01--0.1, followed by transfection with recombinant pJSC1175 plasmids containing fusion genes of *NP* and *M2e*. Subsequently, recombinant vaccinia viruses were screened by blue-white selection. Viral DNA was isolated from each recombinant vaccinia virus to confirm the presence of fusion genes (*NPM2e*, *M2eNP*, *4M2eNP*, and *4M2eNPs*) by PCR and sequencing of PCR products. The confirmed recombinant vaccinia viruses were produced on a large scale in CEFs. The control recombinant vaccinia virus *RVJ1175* was generated using the same method with the empty pJSC1175 vector.

To confirm the expression of NP and M2e by the recombinant vaccinia viruses using indirect immunofluorescence, A549 cells grown in 48-well culture plates were infected with each strain of virus at 30--40 plaque-forming unit (PFU)/well. At 48 h post infection, the cells were fixed with 4% paraformaldehyde, and the expression of β-Gal, NP and M2e was confirmed using mouse monoclonal antibody (MAb) against β-Gal (40-1a), mouse MAb against influenza A virus M2 (14C2), and mouse MAb against influenza A virus NP (5D8). The signals were then visualized using Alexa Fluor^®^ 488-conjugated goat anti-mouse.

Vaccination and Challenge {#Sec6}
-------------------------

SPF female BALB/c (5--6 weeks old) mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). All mice were bred under SPF conditions at the Institute of Laboratory Animal Science, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. Mice were randomly grouped (16 mice/group), inoculated intramuscularly with 1 × 10^7^ PFU recombinant vaccinia viruses (RVJ1175, RVJ-NPM2e, RVJ-M2eNP, RVJ-4M2eNP, or RVJ-4M2eNPs) at week 0 and week 4 in the bilateral gastrocnemius without the use of reagents or equipment.

Ten days after the second immunization, three mice from each group were retro-orbital bled and sacrificed. The spleens were removed aseptically and ground through a 200-mesh sieve. Spleen mononuclear cells (SMNCs) were obtained as described by Wang*et al.* ([@CR35]). The cellular immune responses induced in mice were evaluated by enzyme-linked immunospot (ELISPOT) assay (Wang *et al.*[@CR33]) and the BD CBA Mouse Th1/Th2/Th17 Cytokine kit according to the manufacturer's instructions. Peptides NP55--69, NP147--155, or M2e pooled peptides were used in the ELISPOT and CBA assays. The sera were separated by centrifugation, and serum IgG titers were determined.

Two weeks after the second immunization, mice were anesthetized using sodium pentobarbital (10 mg/mL) at a dose of 60 mg/kg of body weight. Subsequently, 10--12 mice in each group were challenged with 20 times of mouse 50% lethal dose (MLD~50~) of PR8 intranasally. Weight loss and mortality were monitored daily for 3 weeks after the challenge. Mice that lost 30% of their initial weight were euthanized and recorded as having died.

Statistical Analysis {#Sec7}
--------------------

Statistical analysis was performed using SPSS (ver. 17.0; SPSS Inc., Chicago, IL, USA) and Prism (ver. 5.0a; GraphPad Inc., La Jolla, CA, USA). Log conversion was performed for antibody titers. Differences in antibody titer, ELISPOT, and CBA results among groups were analyzed using one-way ANOVA. The paired *t* test and log-rank test were used to analyze differences in weight loss curves and survival rate curves, respectively. Differences with *P* values \< 0.05 were considered statistically significant.

Results {#Sec8}
=======

Construction and Identification of the Recombinant Vaccinia Viruses {#Sec9}
-------------------------------------------------------------------

To generate fusion antigens with the highest potency for inducing cross-protection, we designed a variety of fusion antigen configurations by adjusting the fusion order of NP and M2e, increasing the copy number of M2e (4M2e), and truncating the length of NPs. The *NP* and *M2e* gene fragments of influenza A virus A/Beijing/30/95 (H3N2) were joined to create *NPM2e*, *M2eNP*, *4M2eNP*, and *4M2eNPs* using PCR (Fig. [1](#Fig1){ref-type="fig"}). Each amplified fusion gene fragment was cloned into plasmid pJSC1175 under the regulation of p7.5 early/late promoter. The resulting plasmids pJSC1175-NPM2e, pJSC1175-M2eNP, pJSC1175-4M2eNP, and pJSC1175-4M2eNPs were confirmed by restriction endonuclease digestion and DNA sequencing (data not shown). Each confirmed plasmid was transfected into CEFs infected by vaccinia virus Tiantan strain to facilitate homologous DNA recombination between plasmid and viral genomic DNA. Recombinant vaccinia viruses RVJ-NPM2e, RVJ-M2eNP, RVJ-4M2eNP, and RVJ-4M2eNPs were screened by blue-white selection. The vaccinia virus DNA was extracted to amplify the target gene fragments using PCR. The inserted target genes were confirmed by sequencing of the PCR products.Fig. 1Schematic diagram of NP and M2e fusions. NPM2e: the full-length NP (498 amino acids) precedes one copy of M2e (23 amino acids); M2eNP: one copy of M2e precedes the full-length of NP; 4M2eNP: four copies of M2e precede the full-length of NP; 4M2eNPs: four copies of M2e precede truncated NPs (314 amino acids).

Immunofluorescence Identification of the Expressed Target Proteins {#Sec10}
------------------------------------------------------------------

A549 cells were infected with recombinant vaccinia viruses, and expression of the target proteins (NP and M2e) was identified by immunofluorescence. As a selective marker, β-galactosidase (β-Gal) was expressed at similar levels in A549 cells infected by all recombinant vaccinia viruses. Except the control virus RVJ1175, all other recombinant vaccinia virus expressed M2e and NP in the infected cells. It seemed that RVJ-4M2eNPs showed lower expression of truncated NP than other recombinant vaccinia viruses carrying full-length *NP* gene (Fig. [2](#Fig2){ref-type="fig"}). Flow cytometry analysis of the target protein expression showed similar results, and Western blot analysis confirmed target protein expression at the expected molecular weights (Supplementary Materials).Fig. 2Viral plaque formation and expression of NP and M2e fusions in A549 cells infected by the recombinant vaccinia viruses. A549 cells were infected by RVJ1175 (viral vector control), RVJ-NPM2e, RVJ-M2eNP, RVJ-4M2eNP, and RVJ-4M2eNPs. At 48 h post infection, the infected cells were immunostained by mouse monoclonal antibodies to detect β-galactosidase (β-Gal) (upper panel), influenza NP (middle panel), and M2e (lower panel), followed by incubation with Alexa Fluor^®^ 488-conjugated goat anti-mouse. Microscopic images were showed with 40-fold magnification.

Humoral and Cellular Immune Responses Induced by Recombinant Vaccinia Viruses {#Sec11}
-----------------------------------------------------------------------------

To characterize the immunogenicity of fusion antigens expressed by the recombinant vaccinia viruses, five groups of BALB/c mice were immunized with 10^7^ PFU of recombinant vaccinia virus at week 0 and 4. Ten days after the second immunization, sera were taken to measure the antibody titer, and the spleens were removed aseptically to measure the cellular immune response. Mice immunized with the recombinant vaccinia virus RVJ-NPM2e and RVJ-M2eNP showed strong antibody responses against NP, with lower titers of antibodies against M2e (Fig. [3](#Fig3){ref-type="fig"}A). RVJ-4M2eNP induced strong antibody responses against both NP and M2e. While RVJ-4M2eNPs only induced a strong humoral immune response against M2e but not NP.Fig. 3Humoral and cellular immune responses in BALB/c mice immunized with recombinant vaccinia viruses. Mice were immunized intramuscularly with 10^7^ plaque-forming units of recombinant vaccinia viruses at weeks 0 and 4. Group 1 (G1) mice immunized with RVJ1175 were served as negative controls. **A** Serum was obtained from three mice at 10 days post the second immunization and analyzed by enzyme-linked immunoassay (ELISA) for the presence of IgG antibodies specific for NP (left) or M2e (right), as described in "[Materials and methods](#Sec2){ref-type="sec"}". The columns show geometric mean antibody titers, and the bars indicate the 95% confidence interval in each group (n = 3 mice per group). Comparative results between two groups are shown in the upper table (*ns* not significant, \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 by one-way ANOVA). **B**, **C** Cellular immune response in mice immunized with recombinant vaccinia viruses. Cytokines secreted from stimulated spleen mononuclear cells (SMNCs) were measured by enzyme-linked immunospot (ELISPOT) assay (**B**) and mouse Th1/Th2/Th17 CBA kit (**C**). All mice in each treatment group were sacrificed at 10 days post the second immunization. SMNCs were separated from mouse spleen samples, and 5 μg/mL NP55--69 (left **B**), NP147--155 (middle **B**), and M2e pooled peptides (right **B**, and **C**) were used as stimulants in the ELISPOT and CBA assays. After stimulation for 24 h, the numbers of SMNCs producing interferon (IFN)-γ (**B**) are presented as spot-forming cells (SFCs)/10^6^ SMNCs. The columns show the average SFCs/10^6^ SMNCs, and the bars indicate the standard deviation of each group. Lines above two or more groups indicate that there was no significant difference. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001 by one-way ANOVA.

ELISPOT analysis (Fig. [3](#Fig3){ref-type="fig"}B) revealed that RVJ-NPM2e, RVJ-M2eNP, RVJ-4M2eNP, and RVJ-4M2eNPs induced more NP147--155-specific spot-forming cells (SFCs) than NP55--69-specific SFCs. RVJ-M2eNP induced significantly more NP147--155-specific SFCs than RVJ-NPM2e (*P* \< 0.05) and RVJ-4M2eNPs (*P* \< 0.01). RVJ-4M2eNP also induced significantly more NP147--155-specific SFCs than control virus, nevertheless there is no significant difference compared with RVJ-M2eNP. Except the control virus, all other recombinant vaccinia virus seemed to induce M2e-specific cellular immune responses (Fig. [3](#Fig3){ref-type="fig"}B). However, only M2e-specific SFCs induced by RVJ-M2eNP are significantly more than those induced by control virus (*P* \< 0.01) and by RVJ-NPM2e (*P* \< 0.05).

Cytokine measurements (Fig. [3](#Fig3){ref-type="fig"}C) showed that M2e pooled peptides stimulated SMNCs to secrete several cytokines including interleukin (IL)-2, IL-6, IL-10, and tumor necrosis factor. However, only immunization with RVJ-4M2eNP induced significantly higher levels of IL-2 and IL-10 cytokines than that with control (RVJ1175) when stimulation with the M2e pooled peptides.

Protective Efficacy of the Recombinant Vaccinia Viruses {#Sec12}
-------------------------------------------------------

We assessed the protective efficacy of the recombinant vaccinia viruses in the BALB/c mouse model. Two weeks after the second immunization, BALB/c mice were challenged with 20 MLD~50~ of influenza A virus PR8, and then weight loss and survival rates were monitored for 3 weeks. The weight loss curve (Fig. [4](#Fig4){ref-type="fig"}A) showed that mice immunized with RVJ1175, RVJ-NPM2e, and RVJ-M2eNP experienced rapid weight loss, and all mice died by 9 days post-challenge. Mice immunized with RVJ-4M2eNPs also experienced rapid weight loss; several of these mice died soon after the PR8 challenge, while others experienced maximum weight loss by day 9 post-challenge followed by gradual recovery. Mice immunized with RVJ-4M2eNP experienced the lowest average weight loss (5%) among the groups observed on day 6 post-challenge, followed by rapid recovery to the initial body weight at day 9 post-challenge. The survival rate results (Fig. [4](#Fig4){ref-type="fig"}B) showed that mice immunized with RVJ1175, RVJ-NPM2e, and RVJ-M2eNP died on days 7--8, 7--9, and 7--10, respectively, post-challenge. In contrast, 1/12 mice in the RVJ-4M2eNP died on day 10 post-challenge, showing a final survival rate of 93%. Mice immunized with RVJ-4M2eNPs died on days 7--11 post-challenge with a final survival rate of 30%. Statistical analysis showed that mice immunized with RVJ-4M2eNP had significantly highest survival rate, and mice immunized with RVJ-4M2eNPs also had significantly higher survival rate than the remaining three groups (Fig. [4](#Fig4){ref-type="fig"}B).Fig. 4Protective efficacy of recombinant vaccinia virus containing *NP* and *M2e* genes against 20 MLD50 of PR8. Five groups of mice were immunized with recombinant vaccinia viruses and challenged with 20 MLD50 of influenza virus strain PR8. Among them, mice immunized with recombinant vaccinia virus RVJ1175 served as vector control. Mice were monitored daily for 21 days after PR8 challenge. **A** Mice were weighed daily to monitor morbidity. Average weights in each treatment group were followed for the duration of the study, and the percentage of the original body weight was calculated based on the average starting weight for each group at day 0. **B** Survival rates were calculated and compared among groups. *ns* not significant, \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001.

Discussion {#Sec13}
==========

The extracellular domain of M2e is highly conserved among influenza A virus subtypes (Muñoz-Medina*et al.*[@CR26]; Zebedee and Lamb [@CR40]); thus, it was adopted as a target antigen in the development of a universal influenza vaccine. In the present study, a single M2e induced a poor M2e-specific humoral response (Fig. [3](#Fig3){ref-type="fig"}A, RVJ-NPM2e, RVJ-M2eNP). Four tandem repeats of M2e induced robust antibody response against M2e (Fig. [3](#Fig3){ref-type="fig"}A, RVJ-4M2eNP, RVJ-4M2eNPs), leading to a much stronger cross-protection than that of other groups against heterosubtypic H1N1 influenza virus challenge (Fig. [4](#Fig4){ref-type="fig"}B, RVJ-4M2eNP, RVJ-4M2eNPs). It had been proved that more robust M2e-specific immune response can be induced with multiple copies of M2e (Zhang*et al.*[@CR41]; Zhao*et al.*[@CR44]; Zhou*et al.*[@CR46]), and further enhanced by fusion with an appropriate protein carrier (Ma*et al.*[@CR23]; Zhao*et al.*[@CR43]; Ebrahimi*et al.*[@CR8]; Alvarez*et al.*[@CR3]; Schotsaert*et al.*[@CR30]). Our data suggest that M2e-specific antibody and cellular response played important roles in protection, and 4 × M2e is more favorable than 1 × M2e to induce protective immune response. M2e specific antibody may play a protective role by antibody-dependent cell-mediated cytotoxicity (ADCC), although it could not neutralize influenza virus (Kim*et al.*[@CR17]; Lee*et al.*[@CR20]). Besides, M2e specific cellular immune response may stimulate CD4+ T cells to protect animals (Adler-moore*et al.*[@CR1]).

NP has also been used as a target antigen to develop universal influenza vaccines (Huang*et al.*[@CR14]; Li*et al.*[@CR22]; Wang*et al.*[@CR34]; Nahampun*et al.*[@CR27]; Lei*et al.*[@CR21]; Zheng*et al.*[@CR45]). In the present study, a truncated NP protein lacking 50 amino acids at the N terminal and \~ 70 amino acids at the C terminal was designated as NPs. Although NPs retaining the middle part of NP with multiple conserved epitopes, it showed weaker immunogenicity compared with full-length NP (Fig. [3](#Fig3){ref-type="fig"}A, RVJ-4M2eNP, RVJ-4M2eNPs), and less protection in this experiment (Fig. [4](#Fig4){ref-type="fig"}B, RVJ-4M2eNP *vs* RVJ-4M2eNPs, *P *\< 0.01), probably because of less NP expression (Fig. [2](#Fig2){ref-type="fig"}, middle panel), suggesting that full-length NP is critical toward inducing protective immunity at least in BALB/c mouse. Previous research proved that human MAb against influenza NP played an important role in fighting low-dose infection of influenza virus (Fujimoto*et al.*[@CR11]), and NP might exert a protective effect through ADCC (Kui*et al.*[@CR38]; Jegaskanda*et al.*[@CR15]). Moreover, NP contains numerous conserved CD4+ and CD8+ T-cell epitopes (MacLeod*et al.*[@CR24]; Roti*et al*. [@CR28]), which induce cross-T-cell immune and cross-protective responses (Hayward*et al.*[@CR13]). The present study showed that NP-specific antibody and cellular response played important roles in protection. NP-specific antibody could not neutralize influenza virus just as M2e. However, it may protect animals against challenge by ADCC, antibody-dependent cellular phagocytosis, or antibody-dependent complement deposition, and NP cellular immune response may stimulate CD4+ and CD8+ T cells for protection (Guo*et al.*[@CR12]; LaMere*et al.*[@CR19]); the related mechanism is worthy of further investigation.

Furthermore, we determined whether the immunogenicity of fusion antigens is influenced by the order of NP and M2e. Our data showed that RVJ-NPM2e and RVJ-M2eNP induced similar antigen-specific IgG response (Fig. [3](#Fig3){ref-type="fig"}A, RVJ-NPM2e *vs* RVJ-M2eNP). However, RVJ-M2eNP induced significantly more NP147--155- as well as M2e-specific SFCs than the former one (Fig. [3](#Fig3){ref-type="fig"}B, RVJ-NPM2e *vs* RVJ-M2eNP), suggesting that M2e at N terminal of the fusion antigen is a favorable configuration to induce NP- and M2e-specific cellular immunity. Moreover, our data indicated that four copies of M2e preceding NP (4M2e-NP) is more robust toward inducing NP- and M2e-specific humoral immune response (Fig. [3](#Fig3){ref-type="fig"}A, RVJ-M2eNP *vs* RVJ-4M2eNP) and protection (Fig. [4](#Fig4){ref-type="fig"}B, RVJ-M2eNP *vs* RVJ-4M2eNP). In addition, we observed that only RVJ-4M2eNP immunization induced significantly higher levels of IL-2 and IL-10 cytokines in mice when stimulation with the M2e pooled peptides (Fig. [3](#Fig3){ref-type="fig"}C, RVJ-M2eNP).

Significant progress is made to develop influenza vaccine using viral vectors (Kim*et al.*[@CR16]; Li*et al.*[@CR22]; Tutykhina*et al.*[@CR31]; Dhanwani*et al.*[@CR6]). Several recombinant viral vaccines have been constructed based on modified vaccinia virus Ankara expressing HA, NP, M1, and PB1 antigens (Coughlan*et al.*[@CR5]; Mullin*et al.*[@CR25]; Di Mario*et al.*[@CR7]; Altenburg*et al.*[@CR2]). Vaccinia virus Tiantan strain, developed in China as a vaccine against smallpox, has also been used as viral vector in numerous studies to develop recombinant viral vaccines. In this study, the vaccinia virus Tiantan strain was used to construct recombinant vaccinia viruses expressing fusion antigens with different configurations. The recombinant vaccinia virus expressing 4M2e and full-length NP fusion antigen induced strong cross-protection (92%) against a lethal heterosubtypic PR8 challenge at 20 MLD~50~ and thus regarded as the optimal one among the four constructs. In the previous study, we expressed the fusion protein NM2e in an *E. coli* system, and determined its immunogenicity in BALB/c mice. However, it is inconvenient and time consuming to express and purify much more alternatives. Moreover, it is impossible to express target antigens in an *E. coli* system successfully sometimes. Compared with an *E. coli* system, the recombinant vaccinia virus system has characteristics such as high multiplication capacity, no requirement to purify proteins, and high-efficiency to determine the immunogenicity of target antigens in animal models (Coughlan*et al.*[@CR5]; Mullin*et al.*[@CR25]). In fact, we succeeded in constructing and determining the antigenicity of several fusion antigens of NP and M2e efficiently.

In summary, immunization with a 4 × M2e and NP fusion antigen not only induced NP-specific humoral and cellular immune response, but also increased M2e-specific immunity, which together led to superior cross-protection against heterosubtypic PR8 at 20 MLD~50~. We concluded that the cross- protection potential correlates with both NP and M2e-specific humoral and cellular immune responses induced by RVJ-4M2eNP. However, the recombinant RVJ-4M2eNP containing 4 × M2e and full-length NP could not induce significant neutralizing antibodies, which help to reduce the severity and duration of the illness. Therefore, it is necessary to introduce conserved B-cell epitopes of HA to induce an enhanced cross-neutralizing response and protective potency (Koday*et al.*[@CR18]). Future studies should focus on the development of universal influenza vaccines containing multiple antigens to induce broad neutralizing responses, ADCC, and broad cellular immune responses.
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